Survodutide

Synonyms: BI 456906, GLP-1/Glucagon receptor agonist, 2805997-46-8

Survodutide (BI 456906) is a synthetic peptide dual agonist targeting both the glucagon-like peptide-1 (GLP-1) and glucagon receptors. Developed by Boehringer Ingelheim, it is currently in clinical trials for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The peptide is designed to activate both incretin and glucagon signaling pathways, which together enhance energy expenditure and promote weight loss.

As a research-grade chemical, Survodutide is supplied in lyophilized powder form for laboratory use only. It is not intended for human or veterinary use, but serves as a valuable tool for studying the therapeutic potential of dual GLP-1/glucagon agonism in metabolic diseases.

用途

• Obesity research: Investigating mechanisms of weight loss and energy metabolism.
• Metabolic disease studies: Exploring effects on insulin sensitivity and lipid profiles.
• MASH research: Evaluating potential for treating non-alcoholic steatohepatitis.
• Peptide pharmacology: Understanding dual receptor agonism and downstream signaling.

Ordering & Supply

• パッケージ: Available in vials or bulk containers, custom packaging on request.
• 最小発注数量（MOQ）: 5g
• リードタイム: Typically 1-2 weeks after order confirmation.
• ドキュメント: COA, MSDS, and TDS provided with each shipment.

見積依頼

• 当社の住所: 中国陝西省西安市メインストリート280番地
• リブバイオ株式会社. — メールアドレス： info@lyvbio.com